Evidence map›Paper›PMID 27472396›Full record

ArticleOncotarget2016

Targeting XBP1-mediated β-catenin expression associated with bladder cancer with newly synthetic Oridonin analogues.

Wei Chen, Jiancheng Zhou, Kaijie Wu, Jun Huang, Ye Ding, Eun-Jin Yun, Bin Wang, Chunyong Ding, Elizabeth Hernandez, John Santoyo and 6 more

Open access · diamondAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Oncotarget, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.

0numbers the graph read from it
0cells of the map it votes in
15citing papers in PubMed
2.4field-weighted citation impact, top 11% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

15 citing papers in PubMed, 25 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
  4. Review
  5. Review
  6. Review
  7. Review
  8. Review
  9. Bioactive Natural Spirolactone-Type 6,7-Molecules (Basel, Switzerland) · 2018
    Review
  10. Article
  11. Review
  12. Article
  13. Article
  14. Review
  15. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors at 5 institutions in 3 countries.

Wei ChenDepartment of Urology, The First Affiliated Hospital, Medical School of Xi'an Jiaotong University, Xi'an 710049, China.
Jiancheng ZhouDepartment of Urology, Shaanxi Provincial People's Hospital, Xi'an, Shaanxi 710068, P.R. China.
Kaijie WuDepartment of Urology, The First Affiliated Hospital, Medical School of Xi'an Jiaotong University, Xi'an 710049, China.
Jun HuangDepartment of Urology, The First Affiliated Hospital, Medical School of Xi'an Jiaotong University, Xi'an 710049, China.
Ye DingDepartment of Pharmacology and Toxicology, University of Texas Medical Branch, Galveston, TX 77555, USA.
Eun-Jin YunDepartment of Urology, University of Texas Southwestern Medical Center, Dallas, TX 75390, USA.
Bin WangDepartment of Urology, The First Affiliated Hospital, Medical School of Xi'an Jiaotong University, Xi'an 710049, China.
Chunyong DingDepartment of Pharmacology and Toxicology, University of Texas Medical Branch, Galveston, TX 77555, USA.
Elizabeth HernandezDepartment of Urology, University of Texas Southwestern Medical Center, Dallas, TX 75390, USA.
John SantoyoDepartment of Urology, University of Texas Southwestern Medical Center, Dallas, TX 75390, USA.
Haiying ChenDepartment of Pharmacology and Toxicology, University of Texas Medical Branch, Galveston, TX 77555, USA.
Ho LinDepartment of Life Sciences, National Chung Hsing University, Taichung 40705, Taiwan.
Arthur SagalowskyDepartment of Urology, University of Texas Southwestern Medical Center, Dallas, TX 75390, USA.
Dalin HeDepartment of Urology, The First Affiliated Hospital, Medical School of Xi'an Jiaotong University, Xi'an 710049, China.
Jia ZhouDepartment of Pharmacology and Toxicology, University of Texas Medical Branch, Galveston, TX 77555, USA.
Jer-Tsong HsiehDepartment of Urology, University of Texas Southwestern Medical Center, Dallas, TX 75390, USA.
The University of Texas Southwestern Medical Center · USFirst Affiliated Hospital of Xi'an Jiaotong University · CNThe University of Texas Medical Branch at Galveston · USNational Chung Hsing University · TWShaanxi Provincial People's Hospital · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Conventional chemotherapy is commonly used for advanced stages of transitional cell carcinoma (TCC) with modest success and high morbidity; however, TCC eventually develops resistance. Muscle invasive bladder cancer (MIBC) is recognized as a lethal disease due to its poor response to traditional chemotherapy. Numerous studies have implicated β-catenin, a critical effector in Wnt-mediated pathway associated with epithelial-mesenchymal transition and cancer stem cell, is involved in TCC progression, and furthermore closely associated with chemo-resistance. In this study, we discovered a novel natural product analogue CYD 6-17 that has a potent inhibitory effect on TCC cells exhibiting drug resistance to various chemotherapeutics, with an IC50 at nM range. Delivery of CYD 6-17 significantly inhibited the tumor growth using xenograft model but without detectable side effects. Mechanistically, it targeted β-catenin gene transcription by decreasing the binding of XBP1 to the promoter region, which appeared to be a new regulatory mechanism for β-catenin gene expression. Clinically, XBP1 expression correlated with the poor overall survival of patients. Overall, this study unveils unique mechanism of β-catenin gene regulation in advanced TCC and also offers a potential rational therapeutic regimen to MIBC.

Indexed as

Animalsbeta CateninCarcinoma, Transitional CellCell Line, TumorCell ProliferationComputational BiologyDiterpenes, KauraneEpithelial-Mesenchymal TransitionGene Expression Regulation, NeoplasticHumansInhibitory Concentration 50MiceNeoplasm TransplantationPromoter Regions, GeneticTreatment OutcomeUrinary Bladder Neoplasmsbeta CateninCTNNB1 protein, humanDiterpenes, KauraneoridoninWnt ProteinsX-Box Binding Protein 1XBP1 protein, humanOridonintransitional cell carcinomaWnt pathwayXBP1β-catenin

Identifiers

PMID27472396
PMCPMC5302956
OpenAlexW2503089356

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.